LAVAL, QC / ACCESSWIRE / October 17, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from a retrospective database analysis of adjudicated claims data that examined the impact of access barriers for commercially-insured adults prescribed Xifaxan® (rifaximin) for reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults. Results suggest potentially critical treatment gaps due to access barriers, which may result in increased rates of OHE-related hospitalizations. Findings from the analysis, "Assessment of Access Barriers to Rifaximin Among Patients with Overt Hepatic Encephalopathy Using Adjudicated Claims Data," were presented today at the AMCP Nexus 2023 meeting.
"This study was designed to identify barriers to Xifaxan access among patients with OHE. The study results highlight that rejection of Xifaxan claims led to delay in treatment initiation as well as gaps in active treatment. Such access barriers to Xifaxan may result in increased rates of OHE related hospitalizations," said Arun Jesudian, MD, Director of Inpatient Liver Services at NYPH/Weill Cornell in New York who led the analysis.
Treatment gaps were assessed across a 12-month period that began at the first observed attempt to access rifaximin, which is defined as a paid, reversed or rejected prescription claim.
"Xifaxan is the only FDA-approved medicine indicated for the reduction in risk of overt hepatic encephalopathy recurrence in adults and this analysis shows that many OHE patients continue to face barriers in receiving the vital care they may require," said Nicola Kayel, Senior Vice President, Marketing, Salix. "For the Salix team, our highest priority is patient care. Patients living with OHE continue to be at risk for recurrence and we are committed to understanding and improving the patient journey."
The retrospective database analysis used the IQVIA PharMetrics Plus database linked with Longitudinal Access and Adjudicated Data and identified 1,711 commercially insured adults (aged 18-64) with OHE who had at least one paid rifaximin prescription fill and 12-month continuous eligibility.
About XIFAXAN
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
IMPORTANT SAFETY INFORMATION
To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please click here for full Prescribing Information.
About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the management and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our approximately 90% ownership of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
The XIFAXAN 550 mg product and the XIFAXAN trademark are licensed by Alfasigma S.p.A. to Salix Pharmaceuticals or its affiliates.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
(877) 281-6642 (toll-free)
Media Contact:
Kevin Wiggins
This email address is being protected from spambots. You need JavaScript enabled to view it.
(908) 541-3785
Gianna Scalera
This email address is being protected from spambots. You need JavaScript enabled to view it.
(908) 541-2110
©2023 Salix Pharmaceuticals or its affiliates.
HED.0072.USA.23
Last Trade: | US$6.21 |
Daily Change: | 0.02 0.32 |
Daily Volume: | 1,425,006 |
Market Cap: | US$2.280B |
August 01, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB